Site icon Market Globalist

What Is Driving Salarius Pharmaceuticals, Inc. (SLRX) Stock Up In Pre-Market Session?

AMPE stock

AMPE stock

Shares of biopharma company Salarius Pharmaceuticals, Inc. (SLRX) have been rising +16.58% to $2.25 (as of 09:07 a.m. EST) before the start of the regular session today. The stock has lost -10.65% in the last session closing at $1.93, trading in the range of $1.54 and $2.00 with 2.19 Million shares changed hands.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

What Happened?

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Salarius Pharmaceuticals Inc. is involved in cancer research and developing treatments for cancer patients using the biopharmaceutical industry’s leading-edge technologies. Salarius is investigating seclidemstat, its lead candidate, as a potential treatment for pediatric cancers, solid tumors, and other cancers with treatment options not sufficiently available. The U.S. FDA has already granted Fast Track Designation and Orphan Drug Designation for Seclidemstat for relapsed/refractory Ewing Sarcoma which is in phase 1/2 of clinical trials.

Read More

Salarius today announced the start of the expansion phase of the seclidemstat’s ongoing Phase 1/2 clinical trial in patients with relapsing and refractory (R/R) Ewings and Ewing-related sarcomas. The company will be adopting the following strategy in conducting that expanded study:

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

Exit mobile version